Vir Biotechnology, Inc. quarterly report, Q2 FY2020

Vir Biotechnology, Inc. — Q2 2020 Form 10-Q

Reporting period: Three and six months ended June 30, 2020; unaudited consolidated results. Vir is a clinical-stage immunology company developing treatments and preventives for infectious diseases. It had no approved products and generated no product sales revenue.

Financial results and liquidity

Metric	Q2 2020	Q2 2019	Six months 2020	Six months 2019
Revenue	$67.0 million	$2.0 million	$72.7 million	$5.7 million
Research and development expense	$79.7 million	$29.8 million	$144.6 million	$55.7 million
General and administrative expense	$16.4 million	$8.0 million	$29.0 million	$16.6 million
Net loss	$31.2 million	$33.9 million	$108.4 million	$62.6 million
Operating cash flow	Not separately reported	Not separately reported	$(59.0) million	$(53.8) million

Q2 revenue included $43.3 million recognized from the GSK antibody-program license and $22.7 million from Brii Bio’s exercise of its VIR-2218 China-territory option. These collaboration and license receipts—not product sales—drove the increase.
At June 30, cash and cash equivalents were $371.8 million and short-term investments were $180.6 million; management reported $552.4 million in these resources excluding restricted cash. Total cash, cash equivalents and restricted cash were $384.0 million.
In July, Vir raised $323.2 million net in a follow-on offering. Management said June 30 resources plus the offering proceeds were expected to fund operations for at least 12 months from issuance of the financial statements.
Six-month investing cash flow was positive $114.8 million, largely reflecting investment maturities; financing cash flow was positive $205.4 million, principally from the GSK share issuance. Cash generation therefore did not reflect operating profitability.
Vir reported no debt outstanding. Accumulated deficit was $476.9 million at June 30. No meaningful operating margin was reported; the company remained loss-making.

Changes versus prior comparable periods

Q2 revenue rose by $64.9 million year over year, largely from the GSK and Brii Bio transactions. Six-month revenue increased by $67.0 million.
R&D expense increased $49.8 million in Q2 and $89.0 million for the first half, reflecting COVID-19 program work and manufacturing, higher collaboration and license costs, clinical-trial start-up, and increased personnel.
Despite much higher Q2 operating expenses, the quarterly net loss narrowed to $31.2 million from $33.9 million, aided by collaboration revenue. The six-month net loss widened to $108.4 million from $62.6 million.
Q2 results included substantial non-cash fair-value charges: Humabs contingent consideration increased, and other expense included remeasurement of TomegaVax contingent consideration. Six-month operating cash flow use rose modestly despite the larger net loss, partly because of non-cash charges.
Common shares outstanding increased from 107.6 million at December 31, 2019 to 117.7 million at June 30, 2020; the July follow-on added 8.2 million shares.

Outlook, developments and key risks

Pipeline plans stated in the filing: VIR-7831 was planned to enter a Phase 2/3 COVID-19 trial in August 2020, with initial data anticipated before year-end; VIR-7832 was planned for a Phase 2 trial later in 2020; and preclinical work on VIR-2703 was expected to continue through year-end. These were plans, not guaranteed outcomes.
For HBV, VIR-2218 was in Phase 2; the company reported initial data showing substantial, durable, dose-dependent HBsAg reductions and generally good tolerability. A combination trial with pegylated interferon-alpha had started, as had a Phase 1 trial of VIR-3434. VIR-2482 was in a Phase 1/2 influenza trial and described as generally well tolerated; a Phase 1 trial of HIV candidate VIR-1111 was planned for the second half of 2020.
COVID-19 disruptions had delayed or could delay trial-site activation, enrollment, patient assessments, manufacturing, and other development timelines; Vir specifically reported delays to VIR-1111 and VIR-2482 trials. Management cautioned that the pandemic’s effects remained uncertain.
Vir expects significant operating losses and higher R&D and G&A spending for the foreseeable future and said additional capital will be needed to complete development and commercialization. The stated 12-month runway does not remove that longer-term funding risk.
Manufacturing commitments: The company disclosed approximately $362 million of reserved Samsung capacity and up to approximately $130 million for WuXi batches under earlier binding letters. These arrangements were subsequently assigned to GSKTSL and superseded by MSAs; Vir remained responsible for 72.5% of relevant costs and GSK for 27.5%, subject to terms and exceptions. Vir estimated its aggregate commitments under the Samsung and WuXi MSAs at approximately $482 million, excluding a possible approximately $100 million Biogen access fee. These are material obligations relative to liquidity and depend on manufacturing and program outcomes.
Other notable items include a $10 million Humabs milestone payment following an HBV clinical milestone; a $15 million Alnylam milestone payment and 1,111,111 Alnylam milestone shares; and $35.4 million of contingent consideration at June 30. The filing describes significant estimation uncertainty in contingent-consideration valuations.
COVID-19 antibody development carries competitive, regulatory, clinical, and execution risks. The filing highlights reliance on third-party manufacturers and CROs, possible pandemic-related supply and trial disruption, uncertain regulatory pathways, and the possibility that candidates may not prove safe, effective, approvable, or commercially successful.

Important facts for investors to verify

Whether VIR-7831, VIR-7832, and other pipeline programs met the trial-start and data timelines described as planned, and what subsequent clinical results show.
How the GSK license premium and Brii Bio option exercise affected reported revenue, and whether future collaboration revenue depends on milestones, sales, or cost-sharing arrangements.
The current amount, timing, and enforceable allocation of Samsung, WuXi, and Biogen manufacturing commitments after assignment to GSKTSL and execution of the MSAs.
Cash use, future financing needs, and whether the stated runway remains valid as clinical and manufacturing spending develops.
The assumptions and future changes underlying Humabs and TomegaVax contingent consideration, and any additional milestone or royalty obligations under collaboration and license agreements.
The effect of COVID-19 on trial enrollment, manufacturing supply, and development schedules; the filing provides no assurance that anticipated timelines will be achieved.